BTIG Reiterates Buy on Alto Neuroscience, Maintains $37 Price Target

Benzinga · 1d ago
BTIG analyst Thomas Shrader reiterates Alto Neuroscience (NYSE:ANRO) with a Buy and maintains $37 price target.